Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 2:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 48 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Clostridium Difficile Colitis Clear all
Completed No phase listed Observational

Serum Vancomycin Levels in Patients Receiving Enteral Vancomycin

NCT00617227
View directory record Official record
Conditions
Clostridium Difficle Colitis, Clostridium Difficle Associated Disease
Interventions
Not listed
Lead sponsor
Maimonides Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Feb 10, 2010 · Synced Oct 23, 2026, 2:43 AM EDT
Completed Not applicable Interventional Results available

Enteral Nutrition as Stress Ulcer Prophylaxis in Critically Ill Patients.

NCT01477320
View directory record Official record
Conditions
Gastrointestinal Hemorrhage, Clostridium Difficile Colitis
Interventions
Pantoprazole 40 mg IV daily and tube feed., Placebo and tube feed
Drug · Other
Lead sponsor
Mohamed Saad
Other
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Oct 23, 2026, 2:43 AM EDT
Enrolling by invitation Phase 1 Interventional

Fecal Microbiome Transplant

NCT02636517
View directory record Official record
Conditions
Clostridium Difficile, Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis
Interventions
Fecal Microbiota Transplant
Biological
Lead sponsor
Judith Kelsen
Other
Eligibility
3 Years to 21 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 23, 2026, 2:43 AM EDT
Withdrawn Not applicable Interventional

EGESTA - Emergent GI Therapy for Severe, Complicated CDI Using Fecal Microbiota Transplant

NCT02968511
View directory record Official record
Conditions
C.Difficile Colitis
Interventions
fecal microbiota transplant
Biological
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 27, 2017 · Synced Oct 23, 2026, 2:43 AM EDT
Terminated Phase 4 Interventional Results available

Comparing the Effectiveness of IV Bezlotoxumab Versus Placebo in Decreasing Morbidity and Mortality in Patients With Fulminant C. Diff Requiring Surgery.

NCT03756454
View directory record Official record
Conditions
Clostridia Difficile Colitis, Clostridium; Sepsis
Interventions
Bezlotoxumab, Normal Saline
Biological · Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 23, 2026, 2:43 AM EDT
Completed No phase listed Observational

Vancomycin vs. Nitazoxanide to Treat Recurrent C. Difficile Colitis

NCT00304889
View directory record Official record
Conditions
Clostridium Enterocolitis, Pseudomembranous Colitis, Antibiotic-Associated Colitis
Interventions
Not listed
Lead sponsor
Michael E. DeBakey VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 23, 2026, 2:43 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Fecal Microbiota Therapy for Recurrent Clostridium Difficile Colitis

NCT01973465
View directory record Official record
Conditions
Clostridium Difficile
Interventions
Stool
Biological
Lead sponsor
OSF Healthcare System
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Peoria, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 31, 2013 · Synced Oct 23, 2026, 2:43 AM EDT
Active, not recruiting No phase listed Observational

REMBRANDT: REcovery of the MicroBiome fRom Antibiotics for Dental implanTs

NCT05622721
View directory record Official record
Conditions
Dysbiosis, Clostridium Difficile, Pet-Human Bonding, Antibiotic-Associated Colitis
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 23, 2026, 2:43 AM EDT
Completed Phase 3 Interventional Results available

A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection

NCT05831189
View directory record Official record
Conditions
Clostridium Difficile Infection Recurrence
Interventions
RBX2660
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
12
States / cities
North Little Rock, Arkansas • Camarillo, California • Hamden, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 23, 2026, 2:43 AM EDT
Completed Phase 3 Interventional

A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C.Difficile - Associated Diarrhea

NCT00106509
View directory record Official record
Conditions
Clostridium Enterocolitis, Pseudomembranous Colitis
Interventions
tolevamer potassium-sodium (GT267-004)
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
99
States / cities
Phoenix, Arizona • Rogers, Arkansas • Burbank, California + 81 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Oct 23, 2026, 2:43 AM EDT
Completed No phase listed Observational

Association Between Response to Treatment of C. Diff Colitis and Anti-C.Diff Toxin Antibody

NCT00304408
View directory record Official record
Conditions
Clostridium Enterocolitis, Pseudomembranous Colitis, Antibiotic-Associated Colitis
Interventions
Not listed
Lead sponsor
Michael E. DeBakey VA Medical Center
Federal
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2010 · Synced Oct 23, 2026, 2:43 AM EDT
Terminated Not applicable Interventional

Optimal Surgical Treatment Of Fulminant Clostridium Difficile Colitis

NCT01441271
View directory record Official record
Conditions
Clostridium Difficile Colitis
Interventions
Ileal diversion and lavage, total abdominal colectomy
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 1, 2015 · Synced Oct 23, 2026, 2:43 AM EDT
Not yet recruiting Early Phase 1 Interventional

Prevention of Recurrence of Clostridioides Difficile Colitis With Ursodeoxycholic Acid (UCDA) as a Supplement to Standard Therapy

NCT06884748
View directory record Official record
Conditions
Clostridioides Difficile Infection
Interventions
Ursodiol 500 MG
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 23, 2026, 2:43 AM EDT
Completed Phase 2 Interventional Results available

ICON-2: FMT and Bezlotoxumab Compared to FMT and Placebo for Patients With IBD and CDI

NCT03829475
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Clostridium Difficile Infection
Interventions
Bezlotoxumab, Placebo, Fecal Microbiota Transplantation
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 23, 2026, 2:43 AM EDT
Completed Phase 2 Interventional

A Study of GT160-246 Versus Vancomycin in Patients With Clostridium Difficile-Associated Diarrhea

NCT00034294
View directory record Official record
Conditions
Clostridium Difficile-Associated Diarrhea, Clostridium Enterocolitis, Clostridium Difficile Diarrhea, Antibiotic-associated Colitis, Antibiotic-associated Diarrhea
Interventions
GT160-246
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
58
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Oct 23, 2026, 2:43 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Host Immune Response to Clostridium Difficile Infection in Inflammatory Bowel Disease Patients

NCT01813500
View directory record Official record
Conditions
Crohn's Disease, Ulcerative Colitis, Clostridium Difficile, Inflammatory Bowel Disease
Interventions
Blood and stool sample
Other
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Oct 23, 2026, 2:43 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pathogenic Mechanisms in C Diff Infection and Colitis

NCT01930032
View directory record Official record
Conditions
Clostridium Difficile Infection
Interventions
Not listed
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Oct 23, 2026, 2:43 AM EDT
Recruiting Phase 2 Interventional

Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT)

NCT04305769
View directory record Official record
Conditions
Clostridioides Difficile Infection, Clostridium Difficile Infection, Clostridium Difficile Diarrhea, Clostridia Difficile Colitis
Interventions
Alanyl-glutamine
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 105 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Charlottesville, Virginia • Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 26, 2024 · Synced Oct 23, 2026, 2:43 AM EDT
Completed Phase 3 Interventional Results available

Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection (PUNCH CD3-OLS)

NCT03931941
View directory record Official record
Conditions
Clostridium Difficile Infection, Infection, Communicable Diseases
Interventions
RBX2660
Drug
Lead sponsor
Rebiotix Inc.
Industry
Eligibility
18 Years and older
Enrollment
793 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
46
States / cities
Phoenix, Arizona • North Little Rock, Arkansas • Oxnard, California + 43 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Oct 23, 2026, 2:43 AM EDT
Terminated No phase listed Observational

Small Bowel Transit Time in Clostridium Difficile Colitis

NCT01309750
View directory record Official record
Conditions
Clostridium Difficile Colitis
Interventions
Small Bowel Transit Study
Radiation
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 25, 2017 · Synced Oct 23, 2026, 2:43 AM EDT
Completed No phase listed Observational

Fecal Bacterial Flora in Clostridium Difficile-Associated Diarrhea

NCT00304876
View directory record Official record
Conditions
Enterocolitis, Pseudomembranous Colitis, Antibiotic-Associated Colitis
Interventions
Not listed
Lead sponsor
Michael E. DeBakey VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Baltimore, Maryland • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 10, 2010 · Synced Oct 23, 2026, 2:43 AM EDT
Completed No phase listed Observational

A Multi-Site Clinical Evaluation of the ARIES Clostridium Difficile Assay in Symptomatic Patients

NCT02497417
View directory record Official record
Conditions
Gastroenteritis, Infectious Colitis
Interventions
Not listed
Lead sponsor
Luminex Corporation
Industry
Eligibility
Not listed
Enrollment
1,021 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
4
States / cities
Tampa, Florida • Indianapolis, Indiana • Albuquerque, New Mexico + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2017 · Synced Oct 23, 2026, 2:43 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections

NCT01232595
View directory record Official record
Conditions
Moderate Clostridium Difficile Infection
Interventions
LFF571, Vancomycin (POC)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
14
States / cities
Palm Desert, California • Bristol, Connecticut • Clearwater, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 23, 2026, 2:43 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Trial of a Single Dose of CRS3123

NCT01551004
View directory record Official record
Conditions
Clostridium Difficile Colitis
Interventions
CRS3123, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Oct 23, 2026, 2:43 AM EDT